All In Biotech

Drug Trial Radar · NCT06929299

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

May 12, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous injection in healthy subjects and patients with ITP, and to further explore the initial efficacy of STSA-1301 subcutaneous injection in patients with ITP

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • STSA-1301 subcutaneous injectionDrug

    Subjects will receive the STSA-1301 on the dates specified in the protocol

  • PlaceboDrug

    Subjects will receive the placebo on the dates specified in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate any adverse event that occurs in the subject after administration of the drugTime frame: 78 Days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Xi'an Central Hospital

    Xi’an, Shanxi, China · Recruiting

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.